What a PET Scan Shows vs Hides: Plain-English Guide

PET scans look impressive — bright spots glowing on a body image, three-dimensional rotations on the radiologist's screen. The visual style suggests they show "where the cancer is" with unique clarity. The reality is more interesting and more nuanced. A PET scan does not show anatomy. It shows where cells are doing a particular thing — usually consuming glucose. Some cancers glow brightly; some are invisible. Some inflammations glow even brighter than cancer.

This article unpacks what PET genuinely visualizes, what it cannot see, and why PET-CT (the combined modality) became the clinical standard instead of PET alone.

PET Shows Metabolism, Not Anatomy

A standalone PET scan produces a low-resolution map of where the injected tracer (most commonly F-18 FDG, a glucose analog) accumulates. Each bright spot represents tissue with high metabolic activity. There is no anatomical detail — no organ outlines, no muscles, no bones except where they are metabolically active.

A pure PET image of a normal adult shows:
- The brain (always bright; high glucose use)
- The heart (variable, depending on fasting state)
- The liver (modest baseline brightness)
- The kidneys, ureters, and bladder (FDG excreted in urine)
- Some intestinal activity
- Brown adipose tissue (active in cold patients)

Without anatomical reference, locating a "hotspot" precisely is difficult. Is that bright spot in the lung, the mediastinum, or the chest wall? The metabolic image alone does not say.

Why Doctors Order PET-CT (Combined) Instead

PET-CT, the combined modality now ubiquitous since the early 2000s, fixes the localization problem by co-registering the metabolic PET image with a low-dose CT scan acquired in the same session. The CT provides anatomical structure; the PET provides metabolic activity. Combined, they precisely localize each metabolic finding.

Even better, the CT portion can be diagnostic-quality (with IV contrast) when needed, giving structural information about lesions and surrounding anatomy. Modern protocols routinely produce both.

When a "PET scan" is ordered today, what arrives is almost always a PET-CT. Pure PET scanners are essentially obsolete in clinical practice.

Cancer Cells Glow: The Warburg Effect

In 1924, Otto Warburg described an unusual property of cancer cells: they use glucose at much higher rates than normal cells, and they ferment glucose to lactate even when oxygen is available. This "Warburg effect" is now understood to be a common feature of malignant cells, though not universal.

When FDG (a glucose analog) is injected, cancer cells with active glucose transporters take up the tracer in proportion to their metabolic activity. The most metabolically active tumors — high-grade lymphomas, lung adenocarcinomas, head-neck squamous cell carcinomas — light up dramatically on PET.

The biological signature shows up as an SUV value on the report. A normal tissue SUV of 2.5 is considered roughly the threshold; tumors typically have SUVmax of 4–25+. Higher SUV correlates loosely with more aggressive disease, but not perfectly.

Inflammation Glows Too: Source of False Positives

The FDG mechanism is not exclusive to cancer. Any cell with active glucose metabolism takes up FDG. This includes:

• Inflammation of any cause (infection, autoimmune disease, trauma response)
• Activated immune cells (lymph nodes responding to infection or vaccination)
• Recent surgery (granulation tissue, 4–6 weeks of intense uptake)
• Recent radiation (radiation pneumonitis or esophagitis)
• Sarcoidosis, tuberculosis, fungal infections

This is the single largest source of PET false positives. A patient with active sarcoidosis can have a PET that looks like Hodgkin lymphoma. A patient with a recent pneumonia can have a PET that looks like primary lung cancer. Clinical context matters enormously.

For interpretation when PET findings have unclear etiology, our team can help.

Cold Spots: What Doesn't Show Up

Cancers that PET misses or under-detects:

• Prostate adenocarcinoma — uses fatty acid metabolism, not glucose
• Renal cell carcinoma (clear cell) — low FDG avidity
• Hepatocellular carcinoma — about 50% are FDG-negative
• Well-differentiated thyroid cancer — uses iodine instead
• Mucinous adenocarcinoma — low cellularity
• Neuroendocrine tumors (well-differentiated) — use somatostatin pathway, not glucose
• Bronchioloalveolar lung adenocarcinoma (lepidic spread) — low cellularity
• Lobular breast cancer — diffuse infiltration without focal mass

For these cancers, specialized tracers exist (PSMA for prostate, DOTATATE for NET, radioiodine for thyroid). Ordering FDG PET for prostate cancer staging is often a missed opportunity — the more sensitive PSMA scan should be requested.

Brain and Heart: Naturally Bright on PET

Two organs glow normally on every PET:

• Brain: cortex always intensely bright; uses about 20% of total body glucose despite being only 2% of body mass. This makes PET interpretation of brain disease challenging — you cannot use "FDG uptake" as evidence of brain tumor activity the way you can elsewhere. Instead, neurology PET looks at relative patterns (hypometabolism in dementia, hypermetabolism in tumor recurrence).
• Heart: variable. Patients fasted overnight typically show modest uptake; non-fasted patients show intense uptake throughout the myocardium. Specialized cardiac PET (sarcoid evaluation) requires elaborate dietary prep to suppress this normal uptake.

The bladder is also intensely "bright" on PET because FDG excretes through urine. This is normal but can obscure pelvic lymphoma, prostate, or bladder cancer findings.

Limitations Compared to MRI for Soft Tissue

PET-CT is excellent for metabolic activity and the CT portion gives reasonable structural information. But for fine soft tissue detail, MRI remains superior in many scenarios:

• Brain: MRI shows structural lesions, edema, and contrast enhancement patterns invisible to PET-CT
• Spine: MRI sees cord compression and small bone marrow lesions PET-CT may miss
• Pelvis (gynecologic, prostate): MRI shows tumor extent and adjacent organ involvement in detail
• Musculoskeletal: MRI shows muscle, tendon, ligament, and cartilage detail
• Breast: MRI is more sensitive for primary tumor characterization

For comprehensive staging in some cancers (rectal, prostate, breast, sarcoma), MRI is combined with PET-CT — not replaced by it.

PET Reports: What You'll See Highlighted

A typical PET-CT report focuses on:

• Sites of abnormal uptake with SUVmax values
• Comparison to prior studies when applicable
• Lesion size as measured on the CT portion
• Anatomical localization (e.g., "right paratracheal lymph node, station 4R")
• Differential diagnosis when findings are ambiguous

What you will NOT find:
- Normal anatomy without abnormality is generally not commented on
- Findings outside the cancer-related question are mentioned briefly but not elaborated unless clinically significant
- Microscopic findings (cellular details, mutation status) — PET doesn't show these

Frequently Asked Questions

Why didn't my PET show the cancer my doctor found on MRI?
Some cancers are PET-negative because they don't take up FDG strongly (prostate, RCC, mucinous, well-differentiated). For these, MRI or specialized tracer PET is more sensitive.

Can a PET miss a small cancer?
Yes. PET-CT typically cannot reliably detect lesions under 5–8 mm because of partial volume effects (the scanner cannot resolve smaller structures). LDCT is more sensitive for small lung nodules under 8 mm.

Is a "negative PET" the same as cancer-free?
For FDG-avid cancers, a negative PET is reassuring but not absolute — early-stage disease and small lesions can be missed. For FDG-poor cancers (prostate, RCC, mucinous), a negative FDG PET says little.

Why does my brain always look "bright" on PET?
The brain uses ~20% of total body glucose. Cortical brightness is normal. Brain PET interpretation looks for unusual patterns (hypometabolic regions in dementia, hypermetabolic regions in tumor or seizure focus), not absolute brightness.

Can PET show whether cancer is responding to chemotherapy?
Yes, and this is one of PET's strongest applications. A 30%+ drop in SUVmax across measurable lesions after treatment is the PERCIST criterion for response. PET often detects response weeks before CT shows shrinkage.

Will my PET image be useful 5 years from now?
Yes. Baseline PET-CT is invaluable for future comparison. Store the DICOM files (not just the JPEG report). Many cancer recurrences are detected by subtle changes from a known baseline.

Need Help Booking?

SinoCareLink can pre-book PET-CT (FDG or specialized tracer) at a top Chinese hospital, coordinate clinical interpretation, translate reports into English, and arrange airport pickup. Contact us for a free consultation.